In the past year, we have completed recruitment of all participants for the clinical protocol, Assessment of the Effects of A DPP-4-Specific Inhibitor (Sitagliptin/Januvia) on Immune Function in Healthy Individuals. The research study assays are ongoing. Data collection is complete for many of our assays, including plasma cytokine, microarray on whole blood RNA, flow cytometry on PBMCs. Flow cytometry data collected include Treg analysis and expression of CD26 on lymphocyte subsets. Data for the remaining immune assays including in vitro-stimulated cytokine levels and T cell activation will be completed soon.
|Decalf, Jérémie; Tarbell, Kristin V; Casrouge, Armanda et al. (2016) Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post-translational modification: prospective placebo-controlled clinical studies. EMBO Mol Med 8:679-83|
|Price, J D; Linder, G; Li, W P et al. (2013) Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study. Clin Exp Immunol 174:120-8|